Head & Neck
-
(108-19) ROMAN: A Study to Investigate the Effects of GC4419 on Radiation
Induced Oral Mucositis in Patients With Head/Neck Cancer (Phase 3 clinical trial, appropriate for patients with oral mucositis.)
-
(114-17) Radiation Therapy With or Without Chemotherapy in Treating Patients
With High-Risk Malignant Salivary Gland Tumors That Have Been Removed
By Surgery (Phase 3 clinical trial, appropriate for patients with salivary gland tumors.)
-
(131-17) A Phase 1/2 Safety Study of Intratumorally Administered INT230-6
in Adult Subjects with Advanced Refractory Cancers (Phase 1 clinical trial, appropriate for patients with solid tumors.)
-
(134-17) A Phase IIa trial of sEphB4-HSA in combination with Anti PD-1
Antibody (Pembrolizumab, MK-3475) in patients with non-small cell lung
and head/neck cancer (Phase 2 clinical trial, appropriate for patients with lung, head or neck cancer.)
-
(152-17) Ascending Doses of AZD6738 in Combination With Chemotherapy and/or
Novel Anti Cancer Agents (Phase 1/2 clinical trial, appropriate for patients with advanced solid
malignancies.)
-
(157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid
malignancies.)
- (167-17) Caris ctDNA Validation Project (Research study, appropriate for
patients with all solid tumors.)
-
(180-18) AO-176 in Multiple Solid Tumor Malignancies (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(211-17) Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate
Hepatic Impairment Patients (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(214-17) A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination
with Nivolumab in Advanced Malignant Tumors (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.